Ingeborg A. Hauser

Ingeborg A. Hauser

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Prevalence of Obesity, Comorbidities, and Eligibility for Pre-Transplant Bariatric Surgery in 275 Patients Awaiting Kidney Transplant at a Single Center in Germany.

Prevalence of Obesity, Comorbidities, and Eligibility for Pre-Transplant Bariatric Surgery in 275 Patients Awaiting Kidney Transplant at a Single Center in Germany.

Journal: Annals of transplantation

Published: April 07, 2026

Transplant Nephrectomy: A Comparative Study of Timing and Techniques in a Single Institution.

Transplant Nephrectomy: A Comparative Study of Timing and Techniques in a Single Institution.

Journal: Annals of transplantation

Published: May 07, 2024

Rescue Allocation Modes in Eurotransplant Kidney Transplantation: Recipient Oriented Extended Allocation Versus Competitive Rescue Allocation-A Retrospective Multicenter Outcome Analysis.

Rescue Allocation Modes in Eurotransplant Kidney Transplantation: Recipient Oriented Extended Allocation Versus Competitive Rescue Allocation-A Retrospective Multicenter Outcome Analysis.

Journal: Transplantation

Published: December 11, 2023

Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudy.

Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudy.

Journal: Frontiers in transplantation

Published: August 16, 2023

Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study.

Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study.

Journal: Frontiers in transplantation

Published: July 21, 2023

Riding the Omicron BA.5 Wave: Improved Humoral Response after Vaccination with Bivalent Omicron BA.4-5-Adapted mRNA SARS-CoV-2 Vaccine in Chronic Hemodialysis Patients.

Riding the Omicron BA.5 Wave: Improved Humoral Response after Vaccination with Bivalent Omicron BA.4-5-Adapted mRNA SARS-CoV-2 Vaccine in Chronic Hemodialysis Patients.

Journal: Vaccines

Published: July 21, 2023

Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial.

Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial.

Journal: BMJ open

Published: November 11, 2022

Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.

Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.

Journal: Frontiers in immunology

Published: November 04, 2022

A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program.

A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program.

Journal: Kidney international

Published: August 18, 2022

Increasing but insufficient neutralizing activity against Omicron-BA.1 after a second booster dose of mRNA-1273 vaccine in chronic haemodialysis patients.

Increasing but insufficient neutralizing activity against Omicron-BA.1 after a second booster dose of mRNA-1273 vaccine in chronic haemodialysis patients.

Journal: Clinical kidney journal

Published: June 21, 2022

Risk of graft loss in kidney transplant recipients after aortic valve replacement.

Risk of graft loss in kidney transplant recipients after aortic valve replacement.

Journal: Biomolecules & biomedicine

Published: June 18, 2022

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.

Journal: Leukemia

Published: June 12, 2022

Showing 1-12 of 58

Last Updated: 09/26/2026